Christie
Middle Name
Mitchell
Ballantyne, M.D.
Middle Name
Mitchell
Picture
Christie
Middle Name
Mitchell
Ballantyne, M.D.
Middle Name
Mitchell
Professor
Positions
- Professor
-
Medicine
Baylor College of Medicine
- Professor
-
Molecular and Human Genetics
Baylor College of Medicine
- Professor
-
Molecular Physiology and Biophysics
Baylor College of Medicine
- Director
-
The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Baylor College of Medicine
- Director
-
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
- Co-Director
-
Lipid Metabolism and Atherosclerosis Clinic
Baylor College of Medicine
- J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research
-
Baylor College of Medicine
- Chief of Cardiology
-
Medicine
Baylor College of Medicine
- Chief of Cardiovascular Research
-
Medicine
Baylor College of Medicine
Addresses
- Center for Cardiometabolic Disease Prevention (Clinic)
-
6655 Travis Street, Suite 320
Houston, TX 77030
United States
Phone: (713) 798-5800
https://www.bcm.edu/healthcare/specialties/cardiovascular-medicine/you-and-your-heart/general-cardiology/lipid-metabolism-and-atherosclerosis-clinic
- Section of Cardiovascular Research (Office)
-
One Baylor Plaza, MS BCM285
Suite 524D
Houston, TX 77030
United States
Phone: (713) 798-5034
https://www.bcm.edu/departments/medicine/sections-and-divisions/cardiovascular-research
Education
- Fellowship at Howard Hughes Medical Institute and Institute for Molecular Genetics, Baylor College of Medicine
- 01/1989 - Houston, TX United States
- Clinical Fellowship at Baylor College Of Medicine Affiliate Hospitals
- 01/1987 - Houston, TX United States
- Cardiology
- Residency at University Of Texas Southwestern Affiliate Hospitals
- 01/1985 - Dallas, TX United States
- Internal Medicine
- MD from Baylor College Of Medicine
- 01/1982 - Houston, TX United States
- BA from University Of Texas At Austin
- 01/1977 - Austin, TX United States
- Internship at University of Texas Southwestern Medical School
- Dallas, Texas United States
Certifications
- Cardiovascular Disease
- American Board of Internal Medicine
- Internal Medicine
- American Board of Internal Medicine
- American Board of Clinical Lipidology
Professional Interests
- Clinical and translational research in patients with hereditary lipid disorders for the prevention and treatment of cardiometabolic disease and genetic epidemiology related to lipids and cardiometabolic disease
Professional Statement
Dr. Ballantyne's clinical research focuses on the prevention of cardiometabolic disease. This interest includes pharmacological studies to assess the efficacy and benefits of lipid-lowering drug therapy including trials that examine the effects of lipid-lowering drugs on cardiovascular disease events and the progression of atherosclerosis. As the director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, which serves as the core laboratory for the Atherosclerosis Risk in Communities study, Dr. Ballantyne is studying whether genetic variants in combination with novel biomarkers might be useful in identifying individuals at high risk for cardiometabolic disease and diabetes. Genomics, proteomics, and metabolomics are being used to identify novel molecules that are increased with atherosclerosis, obesity, diabetes, and cardiometabolic disease. In addition, his group is studying new approaches to the prevention and treatment of cardiometabolic diseases with the goal of developing personalized diet, lifestyle, and pharmacotherapy based on the genetic profile and clinical phenotype assessed by proteomics, metabolomics, and imaging.Websites
Selected Publications
- Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL "Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy." Eur J Prev Cardiol. 2020 27 : 593-603. Pubmed PMID: 31357887
- Tang O, Daya N, Matsushita K, Coresh J, Sharrett AR, Hoogeveen R, Jia X, Windham BG, Ballantyne C, Selvin E "Performance of high-sensitivity cardiac troponin assays to reflect comorbidity burden and improve mortality risk stratification in older adults with diabetes." Diabetes Care. 2020 43 : 1200-8. Pubmed PMID: 32161049
- Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM, on behalf of the REDUCE-IT Investigators "Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses." Circulation. 2021 143 : 33-44.
- Antony A, Lian Z, Perrard XD, Perrard J, Liu H, Cox AR, Saha P, Hennighausen L, Hartig SM, Ballantyne CM, Wu H "Deficiency of Stat1 in CD11c+ cells alters adipose tissue inflammation and improves metabolic dysfunctions in mice fed high-fat diet." Diabetes. 2021 70 : 720-32. Pubmed PMID: 33323395
- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators "Effects of icosapent ethyl on total ischemic events: from REDUCE-IT." J Am Coll Cardiol. 2019 73 : 2791-802. Pubmed PMID: 30898607
- Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, for the CLEAR Harmony Trial "Safety and efficacy of bempedoic acid to reduce LDL cholesterol." N Engl J Med. 2019 380 : 1022-32.
- Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM "High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC Study." Circulation. 2019 139 : 2642-53. Pubmed PMID: 31030544
- Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K, Smith SC, Stone NJ, Petersen LA, Ballantyne CM "Applicability and cost implications for PCSK9 inhibitors based on the ODYSSEY Outcomes Trial: insights from the Department of Veterans Affairs." Circulation. 2019 139 : 410-2. Pubmed PMID: 30586689
- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, for the REDUCE-IT Investigators "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia." N Engl J Med. 2019 380 : 11-22. Pubmed PMID: 30415628
- Saeed A, Nambi V, Sun W, Virani SS, Taffet G, Deswal A, Selvin E, Matsushita K, Wagenknecht LE, Hoogeveen R, Coresh J, de Lemos JA, Ballantyne CM "Short-term global cardiovascular disease risk prediction in older adults." J Am Coll Cardiol. 2018 71 : 2527-36.
Log In to edit your profile
